Forian Inc. (NASDAQ:FORA) Q2 2023 Earnings Call Transcript

Forian Inc. (NASDAQ:FORA) Q2 2023 Earnings Call Transcript August 10, 2023

Forian Inc. beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.05.

Operator: Greetings, and welcome to Forian Inc. Second Quarter 2023 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal comments and webcast. Participating today from Forian are Max Wygod, Executive Chairman and Chief Executive Officer; and Michael Vesey, Chief Financial Officer. Before we begin, I'd like to remind you that management's remarks today may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by those forward-looking statements due to a variety of important factors including those discussed in the Risk Factors section of the Company's annual report on Form 10-K for the year ended December 31, 2022 as files with the SEC on March 31, 2023.

Estimating financial performance accurately for future performance is difficult as it involves assumptions and internal estimates that may prove to be incorrect and is based on plans and circumstances that may change. There is, therefore, a significant risk that actual results could differ materially from the outlook provided today. Any forward-looking statements made on the call today represents the company's views as of this date and the company undertakes no obligation to update them except as required by law. Words such as estimate, projected, expect, anticipate, forecast, plan, intend, believe, seek, may, will, should, future, propose and variations of these words or similar expressions or versions of such words or expressions are intended to identify forward-looking statements These statements include, but are not limited to, statements regarding future growth, anticipated performance and prospects.

Today's presenters will also refer to certain non-GAAP financial measures on our call, such as adjusted EBITDA, which the company believes may be important to investors to assess its operating performance and should be considered as supplement to and not a substitute for financial measures prepared in accordance with GAAP. A reconciliation of the comparable GAAP metric can be found in today's press release and webcast, both of which are available on the company's website. Those numbers are unaudited and any statements regarding the company's anticipated performance may be subject to change, including as a result of risks discussed in the Risk Factors section of the company's annual report on Form 10-K filed with the SEC on March 30, 2023. Today's call and webcast is being recorded.

A copy of the recording webcast as well as the full transcript and copies of today's press release and SEC filings will be available at forian.com/investors. I am now pleased to introduce the company's Executive Chairman and Chief Executive Officer, Max Wygod. Sir, you may begin.

Max Wygod: Thank you. Good afternoon, everyone, and thank you for joining us. After the close today, Forian reported fiscal 2023 second quarter results. Our second quarter results reflect success in executing against our long-term strategy. As I stated last call, we are now operating as a health care focused enterprise that has been able to strategically navigate the headwinds of a challenging macroeconomic environment. Forian delivered another quarter of strong operational results with 36% organic year-over-year revenue growth and reached adjusted EBITDA breakeven ahead of schedule. Today, I'll share some highlights from the second quarter and speak to a couple of examples of how our solutions are used, and then Mike will provide details on our financial results.

In the second quarter, Forian delivered strong operational and financial results. Forian's totaled second quarter revenue was $4.9 million, which, as noted, represents 36% year-over-year growth. Our net loss for the quarter was $1.1 million, and our adjusted EBITDA from continuing operations was positive $100,000, reflecting consistent and continued improvement from previous quarters. I’m proud of the team's work in delivering these solid results and hitting the adjusted EBITDA breakeven milestone as we executed on our growth plan despite a challenging macroeconomic environment. As previously reported, in the first quarter, we still saw some pending budgets and discretionary spending and longer sales cycles. Forian's growth has been fueled by our expertise in delivering high-value information solutions to our health care and life science customers.

Our market-leading data assets in our Chronos data lake power solutions ranging from clinical trial development and execution to post-launch commercial analytics to real-world evidence. I'll share a few examples of how our customers are leveraging Chronos to improve their business performance. Given the extraordinary cost of bringing a drug or FDA-approved device to market, life science manufacturers and CROs need actual information to size and quantify market opportunity optimized trial protocol design, test protocol feasibility, identify and select optimal trial sites and conduct Phase 4 post-market surveillance studies. Chronos supports all of these use cases. Life science companies spend tens of billions of dollars each year on marketing to physicians, consumers and health plans.

Upon approval and launch, Forian delivers commercial analytic insights including innovative provider targeting and segmentation solutions, marketing measurement and optimization, market sizing and market share assessments and market access analytics, including drug pricing and assessments of prior authorization and precertification requirements that impact patients' access to therapeutics. In terms of real-world evidence, Chronos maps longitudinal patient journeys on over 300 million de-identified patients in the U.S. on covering in sites such as health care product and service use, drug efficacy and safety, patient compliance and persistence to therapy and health care economics and outcomes research. Real-world evidence is the foundation upon which life science companies understand how their products are being used by whom and to what effect.

It is essential for their development in testing of hypotheses for new drug development, expanding usage to new indications, improving the efficacy, safety and value of a product or service in the real-world. In addition to life science companies, Chronos delivers valuable insights to providers and payers interested in developing efficient, high-quality provider networks, tracking patient leakage to competitor health systems quantifying high-value referring providers to steer patients to their facilities and understanding the dynamics of health care delivery and service use across the systems of care. Our customers appreciate our deep understanding of health care data. Our solution engineers continue to develop and deliver innovative high-value products from Chronos.

In addition, we are beginning to leverage the growing generative AI markets attention to health care. Increasingly, our customers are enabling artificial intelligence solutions trained on Chronos. By doing so, our customers are gaining greater insight into their products, their customers and the dynamics of a rapidly changing marketplace. As the momentum in AI continues, we believe there will be more opportunities to empower clients with more specific data solutions uniquely suited for training advanced AI models on covering unique insights that improve the health care delivery system, support the development of new therapeutics and improved patient outcomes. Finally, we continue to improve our balance sheet. As reported, after the end of the quarter, a customer of Forian in which we held an equity interest was acquired.

Copyright: dizanna / 123RF Stock Photo

And as a result, Forian received approximately $5.9 million of cash proceeds in consideration of all of its equity interest in the customer. Forian may receive additional earn-out payments in 2025 and 2026 and an aggregate amount of up to approximately $3.6 million if certain conditions are met. The additional cash proceeds and operational improvements put for in a strong position. We intend to use the net proceeds for general corporate purposes, including business expansion, deleveraging or the financial and possible acquisitions. Overall, Forian delivered another solid financial and operating quarter, along with the milestone event of reaching adjusted EBITDA breakeven. Our revenue growth, improved margins and cash flow resulted from a committed team executing at a high level, and we look forward to further growth in quarters to come.

I will now hand it over to Mike to go over our financial results in more detail. Mike?

Michael Vesey: Thanks, Max. Today, I’ll provide an overview of Forian’s financial results for the quarter ended June 30, 2023. As previously disclosed in our SEC filings, Forian completed the disposition of BioTrack on February 10, 2023. Through this transaction and the previous dispositions of our Engeni and Security Grade businesses, Forian no longer provides software solutions to the cannabis industry, representing a strategic shift which has a significant impact on operations. Accordingly, we have accounted for the operations of the disposed of businesses as a discontinued operation effective with our first quarter in 2023 and every classified previous reported operating results on a consistent basis. My discussion today will reference comparative results for our continuing operations for the quarter ended June 30, 2023 unless noted otherwise.

The press release issued today presents Forian’s financial results on a GAAP basis. As in prior quarters, we have also reported adjusted EBITDA, which management uses as a measure to track the performance of the business. As noted, the press release and these presentation materials include a detailed reconciliation of adjusted EBITDA to net loss. Our consolidated revenues of $4.9 million for the quarter were up $1.3 million or 36% compared to the same quarter last year. The growth in revenue over the prior year was driven by both new customers and increased revenues from our existing relationships. The majority of our information contracts provided for continuing information deliverables to our customers over a multi-year period, providing a predictable recurring revenue stream on a going forward basis.

Net loss from continuing operations for the quarter decreased $2.9 million from the same quarter last year to $1.1 million. The decrease in net loss was primarily driven by a decrease in loss from continuing operations of $2.4 million, partially offset by changes in other income items such as interest income and taxes. The improvement in loss from continuing operations resulted from the $1.3 million of revenue growth discussed above and a $1.1 million reduction in cost and expenses. The decrease in cost and expenses was primarily due to lower G&A and research and development expenses resulting from the streamlining of our operations after the divestiture of BioTrack. Adjusted EBITDA from continuing operations, which excludes stock-based compensation, depreciation, amortization and certain other non-recurring items was positive $0.1 million compared to negative $2.5 million in the same quarter last year, demonstrating the operating leverage in our streamlining business.

We expect our capital efficient business model to allow us to continue to leverage these investments we made in our infrastructure with a low level of incremental expense growth relative to revenue growing forward. As noted earlier, a reconciliation of our net loss to adjusted EBITDA along with an explanation of the reconciling items is included in today’s earnings release. Turning to our balance sheet. We ended the year with $41.2 million of cash and marketable securities and $25.5 million in convertible notes with no maturities prior to September 2025. It should be noted that these amounts exclude approximately $12.4 million of additional proceeds due from the sale of investments, which will be received in future periods. In July 2023, we received $5.9 million in consideration for a minority interest we held in a customer that was acquired.

We may receive additional earnout payments up to $3.6 million related to this transaction if certain criteria are met. Additionally, we’ll receive monthly payments totaling $6.7 million related to the sale of BioTrack through February 10, 2024, providing additional liquidity to pursue our growth objectives. Our healthcare information revenues were $16.4 million in 2022. We expect 2023 revenues to be in the range of $20.5 million to $22.5 million, reflecting an increase of 25% to 37% over the prior year healthcare information revenues. We expect continued improvements in our net loss and adjusted EBITDA as we continue to leverage our infrastructure achieving a positive EBITDA contribution in the second half of 2023. And with that, I’ll turn the call over to the operator who will open the line for questions.

See also 10 Best Revenue Growth Stocks to Buy and Chuck Royce Portfolio, Performance and Net Worth.

To continue reading the Q&A session, please click here.